Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MRG-201 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| MRG-201 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| MRG-201 | DRUG | Intradermal injection of single ascending doses and multiple ascending doses in healthy volunteers. |
| Placebo | DRUG | Intradermal injection of placebo at a second site in healthy volunteers. Each subject will serve as their own control. |
Inclusion Criteria: * Healthy males between 18 and 45 years of age inclusive * Body Mass Index (BMI) 18-35 kg/m\^2 inclusive * Must have 2 regions on the lower back/upper buttocks free of striae, scars, tattoos or other skin pathologies * If engaged in sexual relations with a female of child-bearin...
MRG-201 is an investigational small molecule being developed by CASI Pharmaceuticals, Inc. It is currently in Phase 1 clinical development. The drug has been studied in a completed clinical trial involving healthy volunteers to assess its safety, tolerability, and pharmacokinetics.
MRG-201 is being studied for use in healthy volunteers, as part of early-phase clinical development. The completed Phase 1 trial focused on evaluating the drug's safety, tolerability, and pharmacokinetic profile in this population. Its therapeutic use in specific diseases has not been established.
MRG-201 is being developed by CASI Pharmaceuticals, Inc., a biopharmaceutical company. The company's stock is traded under the ticker symbol CASI. CASI is responsible for the clinical development of this investigational small molecule drug.
MRG-201 is in Phase 1 clinical development. The drug has completed one Phase 1 trial, which was a randomized, double-blind, placebo-controlled study in healthy volunteers. As an investigational drug, it is not yet approved and remains in clinical development.
MRG-201 has been studied in one completed clinical trial, identified as NCT02603224. This Phase 1 study, titled 'Safety, Tolerability and Pharmacokinetic Study of MRG-201 in Healthy Volunteers,' enrolled 54 male participants in Canada. The trial was randomized, double-blind, and placebo-controlled.
MRG-201 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The drug has completed a Phase 1 trial in healthy volunteers, but it has not yet received regulatory approval for any indication.